echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.

    Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On April 20, Microchip released an announcement that the Phase 2 trial of chidamide combined with envolimab in the treatment of non-small cell lung cancer (NSCLC) patients who have been treated with PD-1 inhibitors has been received from China.
    New Drug Clinical Trial Application (IND) Acceptance Notice issued by the Drug Administration (NMPA).
    This is another recent progress made by the Microchip Technology Innovation Product Pipeline after Sioroni was successively approved for clinical trials in China and the United States.

    Chidamide: Combined with anti-PD-L1 antibody Phase 2 clinical acceptance, Chidamide, independently developed by Chipchip Biosciences, is the world's first subtype-selective histone deacetylase (HDAC) oral inhibitor, which is already in China Approved for the treatment of peripheral T-cell lymphoma and breast cancer indications, and is currently conducting pivotal phase 3 clinical trials in the indications of diffuse large B-cell lymphoma (DLBCL).
    Envolimab (KN035) is a recombinant humanized PD-L1 single domain antibody Fc fusion protein injection that can be injected subcutaneously.
    It has submitted a new drug application in China and has been included in the priority review.
    The indication is standard treatment Failed microsatellite instability (MSI-H)/mismatch repair defect (dMMR) advanced colorectal cancer, gastric cancer and other advanced solid tumors.

    According to the announcement, the NMPA accepted this time is an open, multi-center phase 2 clinical study of chidamide combined with envolimab in the treatment of NSCLC patients who have been treated with PD-1 inhibitors.
    Previously, clinical studies have confirmed that Chidamide's unique mechanism of action is effective for NSCLC.
    According to the results of the Phase 1b/2 clinical trial publicly disclosed at the Annual Meeting of the Association for Cancer Immunotherapy (SITC) in 2018, the objective remission rate of chidamide for patients with advanced non-small cell lung cancer reached 38%, and the disease control rate was 75%, indicating Chidamide has shown a preliminary but relatively clear combination effect in such patients.

    Sioroni: successively approved for clinical trials in China and the United States

    Chiauranib (CS2164) is a multi-target multi-pathway selective kinase inhibitor that can exert comprehensive anti-tumor effects through three active mechanisms, including: ①Inhibition of tumors by inhibiting cell cycle regulatory kinase Aurora B Cell cycle progression; ② inhibit tumor angiogenesis by inhibiting VEGFR and PDGFR related to angiogenesis; ③ inhibit tumor local immunosuppressive cell growth by inhibiting CSF1R related to immune cell proliferation and activation.

    On April 16, Microchip released an announcement stating that a randomized, double-blind, controlled, multi-center phase 3 clinical trial of Cioroni combined with paclitaxel weekly therapy for platinum-refractory or platinum-resistant relapsed ovarian cancer (CHIPRO ) Has also been approved in China.
    On the same day, the company also issued a press release stating that Cioroni has obtained FDA approval to start a phase 1b/2 clinical trial for the treatment of small cell lung cancer (SCLC) in the United States.
    It is worth mentioning that Cioroni's previous clinical studies on small cell lung cancer and ovarian cancer have been included in the breakthrough treatment category in China.


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.